
VeraDermics Inc (MANE) Stock Forecast & Price Target
VeraDermics Inc (MANE) Analyst Ratings
Bulls say
Veradermics is supported by highly differentiated Phase 3 data for VDPHL01, which in Study 304 met both co-primary endpoints and showed stronger hair-count and patient-reported outcomes than Study 302, with 80% to 85% of patients responding and no cardiac-origin adverse events or treatment-related serious adverse events reported. Across more than 1,000 subjects in two male Phase 3 trials, the drug appears superior to low-dose oral minoxidil and topical Rogaine, while its clean tolerability profile and once-daily or twice-daily dosing could accelerate adoption in a market with high willingness to pay. The investment case is further strengthened by the female opportunity, where a ~30 million diagnosed patient population and promising Phase 2 data de-risk the 1H27 female readout and support peak sales potential in the $2.5 billion to $3 billion range.
Bears say
Veradermics is a clinical-stage biopharmaceutical company whose outlook is weakened by concentration risk, since VDPHL01 is its only value-driving asset and remains in late-stage clinical development with no assurance of success in male and female PHL or FDA approval. Even if approved, the company would enter a highly fragmented U.S. market estimated at $9B where cash-pay dynamics, competing Rx, OTC and procedure options, and the possibility of better efficacy or safety from rivals could pressure pricing and adoption. Its dependence on third-party manufacturing, potential API tariffs, and the need for additional capital as operating expenses rise for trials and commercialization further increase execution and financing risk.
This aggregate rating is based on analysts' research of VeraDermics Inc and is not a guaranteed prediction by Public.com or investment advice.
VeraDermics Inc (MANE) Analyst Forecast & Price Prediction
Start investing in VeraDermics Inc (MANE)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About VeraDermics Inc (MANE) Forecast
VeraDermics Inc (MANE) Analyst Forecast & Price Prediction
Start investing in VeraDermics Inc (MANE)
Order type
Buy in
Order amount
Est. shares
0 shares